Risk factors for osteoporosis in postmenopausal African–American women

By Woodson Grattan C.  

Current Medical Research and Opinion, Vol. 20, Iss. 10, 2004-10 ,pp. : 1681-1687

Informa Healthcare

Access to resources Recommend Favorite

A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis

By Gold Deborah T.   Martin Bradley C.   Frytak Jennifer R.   Amonkar Mayur M.   Cosman Felicia  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 585-594

Informa Healthcare

Access to resources Recommend Favorite

Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women

By Ringe J. D.   Christodoulakos G. E.   Mellström D.   Petto H.   Nickelsen T.   Marín F.   Pavo I.  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2677-2687

Informa Healthcare

Access to resources Recommend Favorite

Alendronate reduces osteoclast precursors in osteoporosis

By D’Amelio P.   Grimaldi A.   Cristofaro M.   Ravazzoli M.   Molinatti P.   Pescarmona G.   Isaia G.  

Osteoporosis International, Vol. 21, Iss. 10, 2010-10 ,pp. : 1741-1750

Springer Publishing Company

Access to resources Recommend Favorite

Clinical evaluation of osteoporosis and fracture risk in postmenopausal women

By McClung Betsy  

Clinical Review in Bone and Mineral Metabolism, Vol. 4, Iss. 1, 2006-03 ,pp. : 15-23

Humana Press, Inc

Access to resources Recommend Favorite